News
ORMP
2.920
+3.55%
0.100
Weekly Report: what happened at ORMP last week (0318-0322)?
Weekly Report · 3d ago
Oramed Pharmaceuticals Welcomes New Audit Committee Chair
TipRanks · 03/18 21:33
Oramed Pharmaceuticals Updates Stock Sale Strategies and Partners
TipRanks · 03/18 21:23
Weekly Report: what happened at ORMP last week (0311-0315)?
Weekly Report · 03/18 10:27
Weekly Report: what happened at ORMP last week (0304-0308)?
Weekly Report · 03/11 10:25
ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q4 2023
Oramed Pharmaceuticals reported earnings per share of 33 cents. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -12 cents. Oramed was not a constituent of the S&P 500 Index in the first quarter.
Investorplace · 03/07 15:53
Oramed Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Oramed Pharmaceuticals Inc reports quarterly adjusted earnings of 33 cents per share for the quarter ended in December. The company reported quarterly revenue of zero; analysts expected zero. The average analyst rating on the shares is "hold" for the company. Oramed pharmaceuticals Inc shares had risen by 41.1% this quarter.
Reuters · 03/07 03:17
Weekly Report: what happened at ORMP last week (0226-0301)?
Weekly Report · 03/04 10:27
Weekly Report: what happened at ORMP last week (0219-0223)?
Weekly Report · 02/26 10:35
Oramed Pharmaceuticals CEO Updates Shareholders on Strategy
TipRanks · 02/20 13:52
Weekly Report: what happened at ORMP last week (0212-0216)?
Weekly Report · 02/19 10:37
MQ, ORMP and EXAI are among pre market gainers
MQ, ORMP and EXAI are among pre market gainers. DIH Holdings US (DHAI) +115%. Beamr Imaging (BMR) +72% NVIDIA team up to accelerate adoption of the newest video standard - AV1. ContextLogic (WISH) +38%.
Seeking Alpha · 02/12 13:34
Weekly Report: what happened at ORMP last week (0205-0209)?
Weekly Report · 02/12 10:30
Weekly Report: what happened at ORMP last week (0129-0202)?
Weekly Report · 02/05 10:35
Top 4 Health Care Stocks That May Crash This Quarter
As of Feb. 2, 2024, four stocks in the health care sector are considered overbought. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength when prices fall. An asset is typically considered over bought when the R SI is above 70, according to Benzinga.
Benzinga · 02/02 13:21
Weekly Report: what happened at ORMP last week (0122-0126)?
Weekly Report · 01/29 10:28
Oramed Pharmaceuticals Inc: Current report
Press release · 01/23 22:04
Oramed Pharmaceuticals Said On Jan 22, Co And Unit Entered Into Joint Venture Agreement With Hefei Tianhui Biotech And Technowl; Oramed And HTIT Will Initially Hold Equal Shares In JV, With Each Owning 50% Of Equity
Benzinga · 01/23 21:50
Weekly Report: what happened at ORMP last week (0115-0119)?
Weekly Report · 01/22 10:31
Oramed Pharmaceuticals Inc: Current report
Press release · 01/19 22:05
More
Webull provides a variety of real-time ORMP stock news. You can receive the latest news about Oramed Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company, which is engaged in the research and development of pharmaceutical solutions with its technology platform. Its POD (Protein Oral Delivery) technology has been designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. Its pipeline includes ORMD-0801 diabetes, ORMD-0901, and ORMD-0801 non-alcoholic steatohepatitis (NASH). Its flagship product, ORMD-0801, allows insulin to travel from the gastrointestinal tract via the portal vein to the liver. It is conducting Phase III trials in patients with type 2 diabetes. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone, that stimulates the secretion of insulin from the pancreas. It is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary, Oravax Medical Inc.